Agios (AGIO) downgraded to Hold as Novo Nordisk rivalry and FDA/REMS risks hit sickle cell & thalassemia; pipeline and cash ...
Despite data gaps in many countries, the burden of sickle cell disease, especially in west and central Africa, underscores ...
On Tuesday, the first person in the state to receive gene therapy for sickle cell disease left the hospital after a ...
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
The first Louisiana patient to receive gene therapy for Sickle Cell Disease has left the hospital. Less than 100 people ...
A landmark international study has revealed a sobering public health milestone: Nigeria now carries the highest burden of ...
Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of ...
Novo Nordisk acquired rights to etavopivat when it bought Forma Therapeutics for $1.1 billion in 2022, when the drug was in ...
If the Sickle Cell Disease Protection Act is signed into law by Governor Kemp, the Act would mandate the Georgia Department ...
Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on ...
Topline data for the once-daily PKR activator etavopivat demonstrate a 27% reduction in vaso-occlusive crises and a robust hematologic response in patients with SCD.
Novo Nordisk's etavopivat meets phase III goals, cutting VOCs and boosting haemoglobin in sickle cell disease, with data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results